South Korea · Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 5.22 trillion. The enterprise value is 5.52 trillion.
| Market Cap | 5.22T |
| Enterprise Value | 5.52T |
Important Dates
The next estimated earnings date is Wednesday, July 29, 2026.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Hanmi Pharm. has 12.68 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 12.68M |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 18.03% |
| Float | 6.26M |
Valuation Ratios
The trailing PE ratio is 30.28 and the forward PE ratio is 27.35. Hanmi Pharm.'s PEG ratio is 1.24.
| PE Ratio | 30.28 |
| Forward PE | 27.35 |
| PS Ratio | 3.37 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 4.18 |
| P/FCF Ratio | 33.90 |
| P/OCF Ratio | 25.41 |
| PEG Ratio | 1.24 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.82, with an EV/FCF ratio of 35.84.
| EV / Earnings | 31.99 |
| EV / Sales | 3.56 |
| EV / EBITDA | 17.82 |
| EV / EBIT | 26.20 |
| EV / FCF | 35.84 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.54 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.35 |
| Debt / FCF | 2.72 |
| Interest Coverage | 13.77 |
Financial Efficiency
Return on equity (ROE) is 14.09% and return on invested capital (ROIC) is 11.61%.
| Return on Equity (ROE) | 14.09% |
| Return on Assets (ROA) | 6.25% |
| Return on Invested Capital (ROIC) | 11.61% |
| Return on Capital Employed (ROCE) | 13.26% |
| Weighted Average Cost of Capital (WACC) | 6.41% |
| Revenue Per Employee | 645.63M |
| Profits Per Employee | 71.85M |
| Employee Count | 2,400 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, Hanmi Pharm. has paid 22.12 billion in taxes.
| Income Tax | 22.12B |
| Effective Tax Rate | 10.25% |
Stock Price Statistics
The stock price has increased by +36.75% in the last 52 weeks. The beta is 0.44, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +36.75% |
| 50-Day Moving Average | 480,880.00 |
| 200-Day Moving Average | 443,500.00 |
| Relative Strength Index (RSI) | 38.21 |
| Average Volume (20 Days) | 220,760 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.55 trillion and earned 172.44 billion in profits. Earnings per share was 13,587.92.
| Revenue | 1.55T |
| Gross Profit | 888.10B |
| Operating Income | 210.59B |
| Pretax Income | 215.68B |
| Net Income | 172.44B |
| EBITDA | 309.62B |
| EBIT | 210.59B |
| Earnings Per Share (EPS) | 13,587.92 |
Balance Sheet
The company has 298.38 billion in cash and 418.36 billion in debt, with a net cash position of -119.98 billion or -9,462.08 per share.
| Cash & Cash Equivalents | 298.38B |
| Total Debt | 418.36B |
| Net Cash | -119.98B |
| Net Cash Per Share | -9,462.08 |
| Equity (Book Value) | 1.48T |
| Book Value Per Share | 102,474.33 |
| Working Capital | 345.27B |
Cash Flow
In the last 12 months, operating cash flow was 205.37 billion and capital expenditures -51.45 billion, giving a free cash flow of 153.92 billion.
| Operating Cash Flow | 205.37B |
| Capital Expenditures | -51.45B |
| Depreciation & Amortization | 99.03B |
| Net Borrowing | -58.93B |
| Free Cash Flow | 153.92B |
| FCF Per Share | 12,138.41 |
Margins
Gross margin is 57.32%, with operating and profit margins of 13.59% and 11.13%.
| Gross Margin | 57.32% |
| Operating Margin | 13.59% |
| Pretax Margin | 13.92% |
| Profit Margin | 11.13% |
| EBITDA Margin | 19.98% |
| EBIT Margin | 13.59% |
| FCF Margin | 9.93% |
Dividends & Yields
This stock pays an annual dividend of 1,250.00, which amounts to a dividend yield of 0.29%.
| Dividend Per Share | 1,250.00 |
| Dividend Yield | 0.29% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 7 |
| Payout Ratio | 8.33% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 0.21% |
| Earnings Yield | 3.30% |
| FCF Yield | 2.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Hanmi Pharm. is 596,666.67, which is 49.17% higher than the current price. The consensus rating is "Buy".
| Price Target | 596,666.67 |
| Price Target Difference | 49.17% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 6.64% |
| EPS Growth Forecast (3Y) | 9.00% |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Hanmi Pharm. has an Altman Z-Score of 5.55 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.55 |
| Piotroski F-Score | 6 |